
|Videos|May 23, 2017
Five-Year Follow-Up Results for Nivolumab in NSCLC
Author(s)Julie R. Brahmer, MD
Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab (Opdivo) in previously treated advanced non-small cell lung cancer (NSCLC).





































